Comparison of Pioglitazone vs Glimepiride on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes-Reference-Cited by-同舟云学术

Comparison of Pioglitazone vs Glimepiride on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes

Published:2008-04-02 Issue:13 Volume:299 Page:1561
ISSN:0098-7484
Container-title:JAMA
language:en
Short-container-title:JAMA

Author:

Nissen Steven E.,Nicholls Stephen J.,Wolski Kathy,Nesto Richard,Kupfer Stuart,Perez Alfonso,Jure Horacio,De Larochellière Robert,Staniloae Cezar S.,Mavromatis Kreton,Saw Jacqueline,Hu Bo,Lincoff A. Michael,Tuzcu E. Murat,PERISCOPE Investigators for the

Publisher

American Medical Association (AMA)

Subject

General Medicine

Cited by 784 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic effect of the TyG index on patients with severe aortic stenosis following transcatheter aortic valve replacement: a retrospective cohort study;Cardiovascular Diabetology;2024-08-24

2. Pioglitazone treatment mitigates cardiovascular bioprosthetic degeneration in a chronic kidney disease model;Frontiers in Pharmacology;2024-08-08

3. The effect of hsCRP on TyG index-associated cardiovascular risk in patients with acute coronary syndrome undergoing PCI;Scientific Reports;2024-08-05

4. Effect of tirzepatide on the progression of coronary atherosclerosis using MDCT: Rationale and design of the Tirzepatide treatment on coronary atherosclerosis progression: The (T-PLAQUE) randomized-controlled trial design;American Heart Journal;2024-08

5. Glucagon-like Peptide-1 analogues and delipidation of coronary atheroma in statin-treated type 2 diabetic patients with coronary artery disease: The prespecified sub-analysis of the OPTIMAL randomized clinical trial;Atherosclerosis Plus;2024-06